Enveric Biosciences (ENVB) Net Income towards Common Stockholders (QoQ) (2010 - 2026)
Enveric Biosciences (ENVB) Net Income towards Common Stockholders (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Enveric Biosciences | 5.66 Mn | -2.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 59.57% |
| Dec 31, 2025 | -19.28% |
| Sep 30, 2025 | -34.45% |
| Jun 30, 2025 | -15.30% |
| Mar 31, 2025 | 30.74% |
| Dec 31, 2024 | -51.37% |
| Sep 30, 2024 | -10.89% |
| Jun 30, 2024 | 23.51% |
| Mar 31, 2024 | 28.49% |
| Dec 31, 2023 | -21.75% |
| Sep 30, 2023 | 55.90% |
| Jun 30, 2023 | -33.30% |
| Mar 31, 2023 | 45.45% |
| Dec 31, 2022 | -238.19% |
| Sep 30, 2022 | 9.39% |
| Jun 30, 2022 | 36.51% |
| Mar 31, 2022 | 89.26% |
| Dec 31, 2021 | -1,452.33% |
| Sep 30, 2021 | -198.63% |
| Jun 30, 2021 | 87.73% |